Challenges and Barriers in the Ultomiris Drug Market: An In-depth Analysis
Ultomiris Drug Market Overview Ultomiris (ravulizumab), developed by Alexion Pharmaceuticals (now part of AstraZeneca), is a next-generation complement inhibitor used primarily in the treatment of rare blood disorders such as Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS), Generalized Myasthenia Gravis (gMG), and Neuromyelitis Optica Spectrum Disorder...
0 Commentarios 0 Acciones 48 Views 0 Vista previa
BIZZNANET https://bizznanet.com